Medication info
Trachydio Tablet 2.5/1000 mg

Trachydio Tablet 2.5/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Linagliptin Micronized›2.5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Genewon Science Co., Ltd.
Appearance
Bright pink, biconvex, oval film-coated tablets
Packaging
60 tablets/Alu-Alu [60 tablets (10 tablets/Alu-Alu X 6)]
Approval status
Active

MFDS item code 202201612 · Approved 2022.04.19 · Insurance code 671707360

Summary

Main use
Improves blood glucose control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This drug is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment experience whose blood glucose is not adequately controlled with monotherapy, the initial dose of this drug is 2.5/500 mg, 1 tablet twice daily; this may be increased to 2.5/1000 mg, 1 tablet twice daily. 2. Patients inadequately controlled with metformin monotherapy: The initial dose of this drug should be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this drug should start at their current doses of linagliptin and metformin. 4. Patients inadequately controlled with combination therapy of metformin and a sulfonylurea: The initial dose of this drug should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this drug is administered concomitantly with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, Section 3. Administer with caution to the following patients). 5. Patients inadequately controlled with combination therapy of insulin and metformin: The initial dose of this drug should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this drug is administered concomitantly with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, Section 3. Administer with caution to the following patients). No studies have been conducted to evaluate the safety and efficacy of switching to this drug in patients previously treated with another oral antihyperglycemic agent. Any change in the treatment regimen for type 2 diabetes may result in changes in blood glucose control; caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this drug. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment due to its metformin component (see Precautions for Use, Section 2. Do not administer to the following patients).

Ingredients

Manufacturer
Genewon Science Co., Ltd.

Efficacy & effects

Improves blood glucose control in patients with type 2 diabetes mellitus

View approved original text

This medication is used to help control blood sugar levels in patients with type 2 diabetes, alongside diet and exercise therapy. Linagliptin and metformin work together to effectively lower blood sugar levels. This improvement in blood sugar management contributes to diabetes treatment. Better results can be expected when this medicine is taken regularly along with lifestyle improvements. This medication is used to enhance blood sugar control in patients.

How to take

Adult dose

The dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This drug is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment experience whose blood glucose is not adequately controlled with monotherapy, the initial dose of this drug is 2.5/500 mg, 1 tablet twice daily; this may be increased to 2.5/1000 mg, 1 tablet twice daily. 2. Patients inadequately controlled with metformin monotherapy: The initial dose of this drug should be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this drug should start at their current doses of linagliptin and metformin. 4. Patients inadequately controlled with combination therapy of metformin and a sulfonylurea: The initial dose of this drug should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this drug is administered concomitantly with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, Section 3. Administer with caution to the following patients). 5. Patients inadequately controlled with combination therapy of insulin and metformin: The initial dose of this drug should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this drug is administered concomitantly with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, Section 3. Administer with caution to the following patients). No studies have been conducted to evaluate the safety and efficacy of switching to this drug in patients previously treated with another oral antihyperglycemic agent. Any change in the treatment regimen for type 2 diabetes may result in changes in blood glucose control; caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this drug. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment due to its metformin component (see Precautions for Use, Section 2. Do not administer to the following patients).

Precautions

This medication can cause a rare but serious side effect called lactic acidosis, so caution is required. Lactic acidosis is a condition where lactate accumulates excessively in the blood, leading to serious problems, especially in patients with reduced kidney function or heart disease. This medication should not be administered to patients with certain diseases, such as those with type 1 diabetes, severe renal impairment, acute myocardial infarction or heart failure, liver dysfunction, or pregnant or nursing women. When used with other drugs that lower blood sugar, hypoglycemic symptoms may occur, thus dose adjustment and careful monitoring are necessary. Elderly patients with decreased kidney function or unstable kidney function should undergo regular kidney function tests, and dose adjustments must be made based on kidney function. This medication should be temporarily discontinued in cases of acute illnesses, dehydration, severe infections, and before and after surgery or contrast agent administration for radiological examinations. Rare side effects such as acute pancreatitis or blistering skin conditions may occur, thus if severe abdominal pain or skin abnormalities occur, the physician should be notified immediately. Long-term use may result in vitamin B12 deficiency; if anemia or neurological symptoms arise, blood tests should be conducted, and supplementation may be required. It is advisable to avoid alcohol while taking this medication, and interactions with other medications may occur, so patients should consult with their healthcare providers regarding any medications being taken. Women who are pregnant or planning to become pregnant should not use this medication and should choose other safe methods for blood sugar control. This medication is not recommended for children under 10 years of age, and elderly patients should adjust the dosage considering their kidney function. In the event of overdose, the risk of lactic acidosis increases, necessitating immediate hospital treatment. Store this medication out of the reach of children and avoid moisture.

Side effects

  • Lactic acidosis
  • hypoglycemia
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • reduced and deficient vitamin B12
  • dysgeusia
  • cough
  • decreased appetite
Show 98 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • vesicular pemphigoid
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • constipation
  • upper abdominal pain
  • enterocolitis
  • intestinal obstruction
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • septicemia
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech disorder
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • hepatic metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • pneumonia
  • hyperglycemia
  • dyspnea
  • dizziness
  • drowsiness
  • pruritus
  • insomnia
  • depression
  • hypertension
  • benign prostatic hyperplasia
  • angina
  • acute myocardial infarction
  • unstable angina
  • diarrhea
  • stomatitis
  • mediastinitis
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • gingivitis
  • dyspepsia
  • rectal bleeding
  • cheilitis
  • dental caries
  • enteritis
  • gastritis
  • confusional state
  • nocturia
  • dermatitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture and must be stored in a sealed container. It is important to maintain storage temperatures between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Bright pink, biconvex, oval film-coated tablets

Package unit

60 tablets/Alu-Alu [60 tablets (10 tablets/Alu-Alu X 6)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.